Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database
- 1 April 2020
- journal article
- research article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 61, 101904
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 19 references indexed in Scilit:
- Update in Chronic Obstructive Pulmonary Disease 2016American Journal of Respiratory and Critical Care Medicine, 2017
- Poor adherence to chronic obstructive pulmonary disease medications in primary care: Role of age, disease burden and polypharmacyGeriatrics & Gerontology International, 2017
- Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary DiseaseCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2016
- Global and regional estimates of COPD prevalence: Systematic review and meta–analysisJournal of Global Health, 2015
- How far is real life from COPD therapy guidelines? An Italian observational studyRespiratory Medicine, 2012
- Diagnosis of airway obstruction in the elderly: contribution of the SARA studyInternational Journal of Chronic Obstructive Pulmonary Disease, 2012
- Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroidsInternational Journal of Chronic Obstructive Pulmonary Disease, 2012
- The prevalence of asthma and COPD in Italy: A practice-based studyRespiratory Medicine, 2011
- Epidemiology of COPDEuropean Respiratory Review, 2009
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLOS Medicine, 2006